NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/26/2025
Back to search
Official data from USPTO
ENIGMA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ENIGMA THERAPEUTICS
ST13
US500000098556226Class
5, 42
Filing
98556226
Registration
7911554
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
08/26/2025
Trademark type
Word
Nice classes
5, 42
Filing date
05/17/2024
Registration date
08/26/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/26/2025
Last transaction
08/26/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
24
Owner location
Hertfordshire, GB
Examiner
TORRES, MIGUEL A
Law office
O10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Enigma Therapeutics Ltd.
Representatives
Joe McKinney Muncy Muncy, Geissler, Olds & Lowe, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases and disorders; biotechnological preparations for medical use for the treatment of oncological diseases and disorders; biotechnological preparations for medical use for the treatment of autoimmune diseases and disorders; biotechnological preparations for the treatment of oncological diseases and disorders; biotechnological preparations for the treatment of autoimmune diseases and disorders; antibodies for veterinary use; antibodies for medical use; pharmaceutical preparations containing antigens for the treatment of oncological diseases and disorders; pharmaceutical preparations containing antigens for the treatment of autoimmune diseases and disorders; none of the aforementioned goods for dental purposes
Class 42
Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research services; medicine development services; pharmaceutical research; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; structural and functional analysis of genomes; genetic testing for scientific research; research and development services in the field of immunologybiotechnologyoncologymedicinegene therapyimmunotherapy and therapeutics; research and development services in the field of antibodies and antigens; technological servicesscientific research in the field of pharmaceuticals; technological servicesanalysis in the field of pharmaceuticals; technological servicestesting in the field of pharmaceuticals; laboratory research services relating to the production of monoclonal antibodies; technological servicesscientific research relating to manufacturing methods in the field of pharmaceuticals; advisoryinformation and consultancy services relating to the aforementioned services; none of the aforementioned services in relation to dentistry
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/26/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/10/2025
PUBO
PUBLISHED FOR OPPOSITION
06/10/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/09/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/16/2024
GNRT
NON-FINAL ACTION E-MAILED
12/16/2024
CNRT
NON-FINAL ACTION WRITTEN
12/16/2024
DOCK
ASSIGNED TO EXAMINER
12/03/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/20/2024
NWAP
NEW APPLICATION ENTERED
05/17/2024
Continuous trademark protection
Get notified about every new filing that threatens ENIGMA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.